Eight of these tumours were from patient with other mutation-positive tumours, but importantly, seven of these tumours were from six different patients with tumours classified by Sanger sequencing as wild type, and, thus, they would potentially have been excluded from treatment with BRAF inhibitors when relying on Sanger sequencing alone. The gene discussed is BRAF; the disease is neoplasm.